US$ 26.38
eli lilly glp 1 price cuts for obesity drug Zepbound Lilly and Novo Cut GLP-1
Description
Strong clinical trial results, widespread physician adoption, and high patient preference for oral administration enhance its market leadership
Comparing the results from the various trials [33,38,42,43,44,47,48], the average weight loss is about 3.46.1% of the total body weight

Endocr J 2012;59(10):889-894

COL-1, collagen type I

150 NunesS
The company said it has become the first domestic company to receive approval from the Drugs Controller General of India (DCGI) for the drug